Neurolief

Executive Summary

Neurolief is a privately held Israeli-American medtech company pioneering at-home neuromodulation therapy for neurological and psychiatric disorders. The company's flagship product, Relivion MG, is a wearable device that delivers combined occipital and trigeminal nerve stimulation to provide drug-free relief for acute and preventive migraine treatment. With $60 million raised to date, Neurolief has achieved commercial-stage status and is expanding its footprint in the U.S. migraine market. The device offers a non-invasive, prescription-based alternative to pharmaceutical treatments, addressing a large unmet need among migraine sufferers who are refractory to or intolerant of conventional medications. Early commercial traction and positive clinical data suggest growing adoption by headache specialists and patients seeking non-pharmacological options. Beyond migraine, Neurolief is advancing a pipeline neuromodulation system for major depressive disorder (MDD), representing a significant expansion into the psychiatric market. The company's technology leverages proprietary algorithms to deliver personalized stimulation parameters. Upcoming catalysts include regulatory and clinical milestones for the MDD indication, which could unlock a much larger addressable market. Neurolief's differentiated approach in the neuromodulation space positions it as a compelling player, though it faces competition from other neurostimulation devices and must demonstrate sustained commercial success. The company's ability to secure FDA clearances, generate robust clinical evidence, and forge strategic partnerships will be critical to its long-term growth.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for Relivion MG in major depressive disorder60% success
• Q3 2026Publication of pivotal clinical trial results for MDD neuromodulation system70% success
• Q4 2026Strategic commercial partnership for U.S. or ex-U.S. distribution50% success